Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/09/2022* -- Results Q3 2022 -- -1.75 --
11/09/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
08/05/2022 -- Results Q2 2022 -3.82 -2.25 -69.78%
05/10/2022 -- Results Q1 2022 -1.62 -2.27 28.74%
02/25/2022 -- Results Q4 2021 -2.32 -1.93 -19.96%
02/25/2022 08:30 EST Earnings Call Q4 2021 -- -- --
11/09/2021 -- Results Q3 2021 -1.91 -2.02 5.61%
11/09/2021 08:00 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/09/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/05/2022
Beat/Miss Upgrade
Return Since 3.55%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
URL https://www.biohavenpharma.com
Investor Relations URL https://www.biohavenpharma.com/investors
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 05, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
37.06%
47.21%
57.44%
60.79%
10.44%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-22.58%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-23.58%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
14.82%
19.24%
-13.50%
7.72%
-12.91%
27.86%
0.39%
2.89%
15.48%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
29.66%
As of September 27, 2022.

Profile

Edit
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
URL https://www.biohavenpharma.com
Investor Relations URL https://www.biohavenpharma.com/investors
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 09, 2022 (est.)
Last Earnings Release Aug. 05, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ETCGX 111.47M USD 3.21%
JCNIX 126.48M USD 2.94%
DBMCX 72.36M USD 2.50%
SCSMX 101.82M USD 2.46%
BMEZ 28.90M USD 1.36%
XBI 74.93M USD 1.18%
IBB 73.56M USD 1.01%
IWO 45.80M USD 0.53%
IWM 211.17M USD 0.44%
CSPFX 232.61M USD 0.40%
FSSNX 67.84M USD 0.40%
VTWO 22.03M USD 0.38%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BHVN Tweets